Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Google Secures Pentagon AI Deal for Classified Projects 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
SAN DIEGO and TORONTO, Feb. 18, 2016 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the 2016 RBC Capital Markets Global Healthcare Conference at 10:00 a.m. ET on Wednesday, February 24, 2016 in New York City.
A live webcast of the fire-side chat can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/74205320763.cfm
The audio webcast will be archived shortly after the live event and will be available for 30 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Inc. Greg Chow, CFO 647-479-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
